KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

Novavax (NVAX) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Novavax (NVAX) over the last 15 years, with Q4 2024 value amounting to $48.0 million.

  • Novavax's Accumulated Depreciation & Amortization rose 1707.32% to $48.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.0 million, marking a year-over-year increase of 1707.32%. This contributed to the annual value of $48.0 million for FY2024, which is 1707.32% up from last year.
  • As of Q4 2024, Novavax's Accumulated Depreciation & Amortization stood at $48.0 million, which was up 1707.32% from $41.0 million recorded in Q4 2023.
  • Over the past 5 years, Novavax's Accumulated Depreciation & Amortization peaked at $48.0 million during Q4 2024, and registered a low of $4.3 million during Q4 2020.
  • For the 5-year period, Novavax's Accumulated Depreciation & Amortization averaged around $27.1 million, with its median value being $29.0 million (2022).
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first plummeted by 1568.63% in 2020, then soared by 20232.56% in 2021.
  • Novavax's Accumulated Depreciation & Amortization (Quarter) stood at $4.3 million in 2020, then surged by 202.33% to $13.0 million in 2021, then soared by 123.08% to $29.0 million in 2022, then skyrocketed by 41.38% to $41.0 million in 2023, then increased by 17.07% to $48.0 million in 2024.
  • Its Accumulated Depreciation & Amortization was $48.0 million in Q4 2024, compared to $41.0 million in Q4 2023 and $29.0 million in Q4 2022.